Related Experiment Video

Updated: Sep 13, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

LINC01232 regulates miR-516a-5p/BCL9 axis to promote triple-negative breast cancer progression

Wei Liu1, Yunfeng Niu2, Jie An3

  • 1Department of General Surgery, Bethune International Peace Hospital, No. 398 Zhongshan West Road, Qiaoxi District, Shijiazhuang, Hebei, China. liuweihpyy2023@163.com.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|July 30, 2025
PubMed

Insights

Triple-negative breast cancer (TNBC) involves high LINC01232 levels. Inhibiting this long non-coding RNA (lncRNA) reduces TNBC cell growth and spread by affecting the miR-516a-5p/BCL9 pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Triple-negative breast cancer (TNBC) lacks targeted therapies and has a poor prognosis.
  • The role of long non-coding RNAs (lncRNAs) in TNBC pathogenesis is an area of active investigation.
  • Identifying novel molecular pathways is crucial for developing effective TNBC treatments.

Purpose of the Study:

  • To investigate the function of the lncRNA LINC01232 in TNBC.
  • To elucidate the regulatory mechanism of LINC01232 involving the miR-516a-5p/BCL9 pathway.
  • To assess LINC01232 as a potential therapeutic target for TNBC.

Main Methods:

  • Quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure LINC01232 expression in TNBC tissues.
  • Luciferase reporter assays and cellular function tests to analyze the interaction between LINC01232, miR-516a-5p, and BCL9.
  • In vitro experiments evaluating the impact of LINC01232 silencing on TNBC cell proliferation, migration, and invasion.

Main Results:

  • LINC01232 expression was significantly upregulated in TNBC tissues compared to normal tissues.
  • Silencing LINC01232 inhibited proliferation, colony formation, migration, and invasion of breast cancer cells.
  • LINC01232 acts as a competing endogenous RNA (ceRNA) for miR-516a-5p, leading to increased BCL9 expression.

Conclusions:

  • LINC01232 promotes TNBC malignant progression via the miR-516a-5p/BCL9 pathway.
  • LINC01232 represents a potential diagnostic biomarker and therapeutic target for TNBC.
  • This study offers new insights into the molecular mechanisms underlying TNBC development.

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K